Invivyd

Invivyd

I’m ready to call it. This drug is incredible. Long Haulers need it. Just a couple of weeks along, I’m seeing what others w/ Long COVID report. These antibodies are powerful- WE NEED A TRIAL!!

My nightmare began in Jan ‘24. Today I feel Perfect
 
Mij said:
Invivyd

I’m ready to call it. This drug is incredible. Long Haulers need it. Just a couple of weeks along, I’m seeing what others w/ Long COVID report. These antibodies are powerful- WE NEED A TRIAL!!

My nightmare began in Jan ‘24. Today I feel Perfect
Click to expand...


I have to say I feel pretty skeptical about anti sars cov2 monoclonals as a long covid treatment. I just haven't seen much compelling evidence that viral persistance is a driver of symptoms.

And all the antiviral drugs that have been tried so far have had no efficacy.
 
Reply from an infectious disease doctor to a LC/ME/CFS patient:

Hi Rachel. For non-Covid related MECFS, of which I treat a large populous, I do not believe the monoclonal would be effective however I do take proactive approaches towards root cause, despite it being a bit more difficult, as it’s far more variable. You may DM re: consult.

 
Mij said:
however I do take proactive approaches towards root cause, despite it being a bit more difficult, as it’s far more variabl
Click to expand...

What does this even mean? We don't know the root cause of ME/CFS. This is exactly what I'm talking about, the viral persistence lot seem to have an assumption of cause that preceeds or superceeds the need for evidence.
 
From Dr. Scoma website:

Chronic Fatigue Syndrome (CFS), also known at Myalgic Encephalomyelitis (ME) is a complex and debilitating condition characterized by profound and persistent fatigue, non-restorative sleep, post-exertional malaise (PEM), cognitive impairment, and orthostatic intolerance. Dr. Scoma’s approach to treating ME/CFS and expertise lies in integrating a complex, multidisciplinary strategy that combines advanced diagnostics with personalized treatment plans. This includes:

■ Identification and treatment of viral reactivation including Epstein Barr virus, HHV-6, Parvovirus-B19, and Enterovirus species.
■ Treatment of sleep problems including insomnia, non-restorative sleep, hypersomnia, sleep fragmentation, and Restless Leg Syndrome (RLS).
■ Identification and treatment of dysfunction of the autonomic nervous system (ANS) as well as orthostatic intolerance.
■ Multifaceted and complex treatment regimens for fatigue and post-exertional malaise (PEM) aimed at pacing and energy management coupled with proactive, cutting-edge pharmacotherapy and
supplementation.
 
You must log in or register to reply here.
Back
Top Bottom